Clinical Trials Logo

Clinical Trial Summary

The aim of this study was to determine serum levels of VEGF, sVEGFR1, VEGFR2, IGFBP-3, angiogenin and endoglin in patients with larynx squamous cell carcinoma; investigate their association with clinical parameters and determine their diagnostic and prognostic value.


Clinical Trial Description

Although there has been a significant increase in survival in many other cancer types through the years, no significant increase has been achieved in laryngeal SCC survival rates in the last 50 years. Despite the advancements in surgical techniques, organ preservation protocols and multidisciplinary approach, significant amount of patients have been living with morbidity or dying due to recurrence and metastasis. This lack of significant improvement in mortality rates creates the need for reliable and accurate biomarkers in early diagnosis, treatment and follow-up. Considering that the prognosis of two patients at the same clinical stage and treated with the same treatment protocol may differ, it suggests that there may be some differences at the molecular level apart from clinical stages. This study was mainly prepared to determine serum levels of VEGF, sVEGFR1, VEGFR2, IGFBP-3, angiogenin and endoglin in patients with larynx squamous cell carcinoma; investigate their association with clinical parameters and determine their diagnostic and prognostic value. To reach these aims, 60 patients who were prospectively and consecutively recruited from those who admitted to Hacettepe University, Department of Otorhinolaryngology, Ankara, Turkey, and were diagnosed with LSCC between May 2018 and February 2020. 20 healthy and age-matched controls were chosen from the hospital staff and relatives of the patients. Serum samples were obtained from all participants at the time of diagnosis, centrifuged and stored at -80 C. ELISA method will be used to analyze the serum levels of VEGF, sVEGFR1, VEGFR2, IGFBP-3, angiogenin and endoglin. Data analysis will reveal if there are any association between biomarker candidate molecules and clinical parameters. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05217147
Study type Observational
Source Hacettepe University
Contact
Status Completed
Phase
Start date May 1, 2018
Completion date August 31, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT06016699 - Immunological Function After Radiation With Either Proton or Photon Therapy
Completed NCT03292341 - Evaluation of a Web-based Decision Aid Tool for Larynx Cancer (T3/T4) Patients. N/A
Completed NCT03653039 - Comparison Between a Standard Tube and the Ultra-thin Tritube for Intubation of the Trachea and for Maintaining Access to the Trachea After Anaesthesia, in Patients With an Expected Difficult Direct Laryngoscopy N/A
Completed NCT05746780 - Bilateral Elective Neck Dissection in Salvage Total Laryngectomy
Recruiting NCT05793151 - Multi-Site Trial of Navigation vs Treatment as Usual for Delays in Starting Adjuvant Therapy N/A
Completed NCT01700647 - Breath Testing in Early and Late Larynx Cancer N/A
Completed NCT00169247 - Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation Phase 2
Completed NCT00600223 - Functional Voice and Speech Outcomes Following Surgical Voice Restorations: A Comparison of Pharyngeal Construction Approaches N/A
Recruiting NCT03759431 - Vocal-cord vs. Complete Laryngeal Radiotherapy for Early Glottic Cancer Phase 2
Active, not recruiting NCT02586207 - Pembrolizumab in Combination With CRT for LA-SCCHN Phase 1
Recruiting NCT04057209 - VoiceS: Voice Quality After Transoral CO2-Laser Surgery Versus Single Vocal Cord Irradiation for Larynx Cancer N/A
Recruiting NCT04028479 - The Registry of Oncology Outcomes Associated With Testing and Treatment
Recruiting NCT06086119 - Quality of Life and Voice Perception in Patients Laryngoctomized Phonatory Wearers
Suspended NCT04368702 - CONFIRM: Magnetic Resonance Guided Radiation Therapy N/A
Active, not recruiting NCT03082534 - Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma Phase 2
Completed NCT00158652 - Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC Phase 3
Terminated NCT03479463 - Use of Human Dehydrated Amnion Chorion Allograft in Laryngectomy/Pharyngectomy
Completed NCT03096808 - Adaptive Radiotherapy for Head and Neck Cancer Phase 2
Completed NCT03028766 - WEE1 Inhibitor With Cisplatin and Radiotherapy: A Trial in Head and Neck Cancer Phase 1
Completed NCT00359645 - Randomized Trial to Assess the Impact of a Screening Program on Upper Aerodigestive Tract Cancer Mortality in a High Risk Population Phase 3